Mechanism of Action: Estrogen Receptor Antagonists
✉ Email this page to a colleague
Drugs with Mechanism of Action: Estrogen Receptor Antagonists
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | FASLODEX | fulvestrant | SOLUTION;INTRAMUSCULAR | 021344-001 | Apr 25, 2002 | AO | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Astrazeneca | FASLODEX | fulvestrant | SOLUTION;INTRAMUSCULAR | 021344-002 | Apr 25, 2002 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
Fresenius Kabi Usa | FULVESTRANT | fulvestrant | SOLUTION;INTRAMUSCULAR | 210326-001 | May 20, 2019 | AO | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
Fresenius Kabi Usa | FULVESTRANT | fulvestrant | SOLUTION;INTRAMUSCULAR | 210326-001 | May 20, 2019 | AO | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | ||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |